Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I was surprised to see the name Hudson as well. Weird stuff. Lots of buys afterwards though but now strange trading where it's a standoff with .001 cents. Hahaha. Interesting times. Sure looks like this baby is going to break one way or the other. Good luck everyone.
13G/a filed.
Thanks for this! There has been obvious accumulation last few days. Hopefully some good times ahead for share holders. The big question is if they want to dilute or not.
Well at least short term it may be a decent play as I had an order in all day yesterday for 10,000 at .27 and zero filled.
Tough call as looking like accumulation but could be a head fake. Do I buy some now is the question. Hmmmm
So far no trades since just before 8k. Acting like halted lol
Yup this may bode very, very well for share price. :)
Another interesting filing several minutes ago. Court case dismissed and shares outstanding now 10,569,454
Today's filing! Interesting. Did they actually get rid of those nasty warrants???....
Item 1.01 Entry into a Material Definitive Agreement.
On December 27, 2018, Delcath Systems, Inc. (the “Company”) entered into Exchange Agreements with institutional investors (the “Holders”) with respect to the following previously issued to Holders of those certain Warrants to Purchase Common Stock (the “Existing Warrants”), issued to the Holders on February 9, 2018 (pursuant to (i) that certain Placement Agency Agreement, dated February 8, 2018, (ii) the Company’s Registration Statement on Form S-1 (File number 333-220898) and (iii) the Company’s final prospectus dated as of February 8, 2018) and which Existing Warrants are currently exercisable into 320,000 shares of Common Stock (as defined in the Existing Warrants). The Company issued to the Holders 320,000 shares of Common Stock (the “Exchange Shares”) in exchange for the Existing Warrants (the “Exchange”). The Exchange was made in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended. Concurrently therewith, the Holders have each executed and delivered to the Company a leak-out agreement which contains certain trading restrictions with respect to the Exchange Shares.
Besides 8k released on 24th now official news this am....
Delcath Announces Commercial Licensing Agreement for CHEMOSAT(R)
7 Year Agreement with medac to Maximize Potential of CHEMOSAT in Europe
Upfront and Milestone Payments Provide Additional Resources to Advance Clinical Development in the U.S.
NEW YORK, Dec. 26, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the company has entered into a definitive licensing agreement for CHEMOSAT(R) commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac), a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases. The company has offices globally, worldwide partner agreements in over 90 countries, and approximately 1,200 employees.
Under the terms of the seven-year agreement, Delcath's European subsidiary, Delcath Systems, Ltd. exclusively licenses medac to sell and market CHEMOSAT in all member states of the European Union, Norway, Liechtenstein, Switzerland, and the United Kingdom. medac will pay Delcath EUR6,000,000 in a combination of upfront and success-based milestone payments. Additionally, Delcath will receive a fixed transfer price per unit of CHEMOSAT as well as royalties. The agreement has a projected value of up to $45 million over the first seven-year term and includes an optional five-year extension.
"With offices throughout Europe and a well-established network among oncology key opinion leaders, medac is a well-suited partner to help advance CHEMOSAT commercialization in the European Union and neighboring countries," said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath. "medac provides the organizational scale, expertise and market reach necessary to help us strive to firmly establish CHEMOSAT in the European treatment landscape for cancers of the liver. Additionally, through this agreement, we obtain immediate resources to support our efforts to advance our clinical development program. This is a highly significant development for Delcath, and we are pleased to be working with a market leader like medac to help this therapy fully realize its potential."
Heiner Will, Chief Marketing Officer of medac, said, "We are excited to build upon the growing customer and revenue base that Delcath has built in Europe to provide patients with liver metastases a promising treatment modality. We are convinced by the assessment of European clinicians about the very meaningful impact CHEMOSAT has on the quality of life of these patients who, because of the safety profile of CHEMOSAT can receive multiple treatments." This substantial new business opportunity strengthens and expands medac's expertise in the treatment of cancer. medac is currently working diligently with Delcath launching commercial efforts in Europe in January 2019.
About Delcath Systems
Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. Our investigational product -- Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) -- is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. We have been enrolling a global Registration clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM) called The FOCUS Trial and have initiated a global Phase 3 clinical trial for intrahepatic cholangiocarcinoma (ICC) called The ALIGN Trial. Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system has been commercially available since 2012 under the trade name Delcath Hepatic CHEMOSAT(R) Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide range of cancers of the liver.
About medac
medac Gesellschaft für klinische Spezialpräparate mbH is a privately held pharmaceutical company with a growing pharmaceutical and diagnostics business. Established in the Hamburg area, medac provides a range of high-quality basic and speciality therapeutics within oncology and haematology, autoimmune diseases and urology. Approximately 1,200 employees work together in development, manufacturing and commercialization of pharmaceutical drugs. This makes medac products available in more than 90 countries.
Forward Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the timing and results of the Company's clinical trials including without limitation the OM and ICC clinical trial programs, timely enrollment and treatment of patients in the global Phase 3 OM and ICC clinical trials, IRB or ethics committee clearance of the Phase 3 OM and ICC Registration trial protocols from participating sites and the timing of site activation and subject enrollment in each trial, the impact of the presentations at major medical conferences and future clinical results consistent with the data presented, approval of Individual Funding Requests for reimbursement of the CHEMOSAT procedure, the impact, if any of ZE reimbursement on potential CHEMOSAT product use and sales in Germany, clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe including the key markets of Germany and the UK, the Company's ability to successfully commercialize the Melphalan HDS/CHEMOSAT system and the potential of the Melphalan HDS/CHEMOSAT system as a treatment for patients with primary and metastatic disease in the liver, our ability to obtain reimbursement for the CHEMOSAT system in various markets, approval of the current or future Melphalan HDS/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the U.S. and/or in foreign markets, actions by the FDA or other foreign regulatory agencies, the Company's ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same, uncertainties relating to the timing and results of research and development projects, and uncertainties regarding the Company's ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
(END) Dow Jones Newswires
December 26, 2018 08:00 ET (13:00 GMT)
You have to be kidding right? ?? Cover you're short man. That's pretty desperate to try and make this news look anything but amazing.
Interesting filing after hours. Usually I don't like Friday after hours news but this one is interested to say the least. ??
Who's falling for this? When it stayed at .50 for a bit it looked to be turning. Now in this range looks as well but I'm not falling for it.
10q is out now. Some interesting stuff in there.
Why? .02 might not be a good price. No sign yet that this won't be subpenny soon. Sad
When people were saying .05 I thought no chance. Now I can see it easily going below that. I definitely played the deadcat bounce on this one wrong. They got me. It's on me but I was prepared to lose all my money. It could have easily had a short term huge rebound. No risk, no reward. I won't be averaging down this time. Good luck everyone!
Why??? No thanks!
Filing after hours for some preferred shares. ??
Amazing just hit .32 mid day. Interesting how few shares are on the bid side.
You are correct! Nobody knows. The few shares sold yesterday at just over .50 are now replaced with a .57 bid. This could sky rocket or drop hard in the coming days/weeks/months. Place your bets everyone! :)
You are correct! Nobody knows. The few shares sold yesterday at just over .50 are now replaced with a .57 bid. This could sky rocket or drop hard in the coming days/weeks/months. Place your bets everyone! :)
Nice prediction. What did you do to come up with that number if you don't mind me asking?
Tide is finally turning to the bulls on early buy volume. Looking good.
I'm not so sure this is bad. I suggest everyone read the whole filing. Interesting stuff. :)
Form S-3 filed. Might explain where shares came from.
They are skilled! I have no clue when to play this for a short term gain. Seems like the flood gates keep staying open. They win this time I think as I refuse to average down. It could easily jump to dollars or go to pennies, even sub pennies. They WIN unfortunately but it is a game.
Not sure good entry as I can't figure out where all the cheap shares came from in the first place. I made a killing back when it skyrocketed after reverse split was voted down but this time I'm not so lucky.
They whole stock market is a scam. Play it right.
Same boat here. We may be out of luck for the quick flip as there seems to be way too much selling pressure right now.
Interesting from this morning's filing...
As of the close of the trading day on October 16, 2018, Delcath had 6,792,137 shares of its Common Stock issued and outstanding.
Not sure if anyone else feels the same but I think the drop in stock due to the "family squabble" is overblown and some serious turnaround is about to happen. ??
Snipp is finally going to bust out in 2018. Stars are aligning for this great company.
Just my opinion of course. Do not sell. 2018 is going to be much different. This thing is held so tight and catalysts are going to push this to new highs not seen in few years.
Cheers!
First of many good news releases for 2018. ??
https://ih.advfn.com/p.php?pid=nmona&article=76397498
I wanted to start this board to state that in my opinion 2018 will be a remarkable year for Snipp. Watch for a new 52 week high early in 2018 then a push to the .80-.90 we saw in 2015 by the middle of the year.
Profits are going to show this year and big things are in the works in my opinion.
Cheers!
The $5 warrants will be in the money by early 2018 in my opinion. I have been trading for a long time. Much of this is a game regardless of news. From what I have seen so far this company is all for supporting share price increase. Without that it doesn't matter what news comes out. If I see that changing I will re-evaluate.
Check out their Facebook page...
https://www.facebook.com/GlanceTechCorporate/
There app is very nice. Expect news of US market penetration to get this stock to the next level.
Boo. Wanted to be the first to post here. :) Just wanted to say I feel this stock will kick a$$ in 2018. So much potential. Usually financing keeps a stock down for a while but I think this one will be running again soon. Cheers